Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis

Background Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving intertriginous skin. Previous epidemiologic studies have been limited by small sample size. Objective We sought to describe the prevalence and comorbidities of HS in a large patient care database. Methods In this re...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2014-12, Vol.71 (6), p.1144-1150
Main Authors: Shlyankevich, Julia, MD, Chen, Allison J., BA, Kim, Grace E., BS, Kimball, Alexandra B., MD, MPH
Format: Article
Language:English
Subjects:
acne inversa
Adult
Aged
Alcoholism - epidemiology
cardiovascular disease
Case-Control Studies
comorbidities
Comorbidity
Databases, Factual - statistics & numerical data
Dermatology
Diabetes Mellitus - epidemiology
Dyslipidemias - epidemiology
Female
hidradenitis
hidradenitis suppurativa
Hidradenitis Suppurativa - epidemiology
Humans
Hypertension - epidemiology
lymphoma
Lymphoma - epidemiology
Male
metabolic syndrome
Middle Aged
obesity
Obesity - epidemiology
Prevalence
Retrospective Studies
Smoking - epidemiology
Substance-Related Disorders - epidemiology
Thyroid Diseases - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving intertriginous skin. Previous epidemiologic studies have been limited by small sample size. Objective We sought to describe the prevalence and comorbidities of HS in a large patient care database. Methods In this retrospective case-control study, we chart-validated all patients within a hospital database who received at least 1 billing code for HS between 1980 and 2013. Verified cases were matched with controls based on age, gender, and race. Prevalences of a priori selected comorbidities were compared between HS and control groups. Results A total of 2292 patients at Massachusetts General Hospital received at least 1 code for HS. A total of 1776 cases had a validated diagnosis of HS, yielding a prevalence of 0.08%. In unadjusted analysis, all comorbidities were diagnosed significantly more in HS compared with control including (in rank order of likelihood): smoking, arthropathies, dyslipidemia, polycystic ovarian syndrome, psychiatric disorders, obesity, drug dependence, hypertension, diabetes, thyroid disease, alcohol dependence, and lymphoma (all P < .01). Limitations Control subjects were not validated for absence of HS and comorbidity validation was not performed for either group. Conclusions Our results highlights the high comorbidity burden of patients with HS compared with matched control subjects.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2014.09.012